INSM shorts rebuild while Morgan Stanley trims ahead of October 29 print

Insmed enters its October 29 earnings report with short sellers rebuilding positions at a pace that stands out against a peer group that has largely moved the other way this week.

Short interest has climbed to 6.54% of free float, up 22% over the past month and roughly 1.2% over the past week alone. The jump is most visible in the absolute share count: from around 10.9 million shorted shares at the start of October to nearly 14 million now, a move that began abruptly on October 9 and has held. Yet the borrow market shows no stress. Cost to borrow is just 0.45%, down 21% on the week after a brief spike in mid-October. Availability is vast, running at nearly 4,800% relative to short interest, meaning the lending pool is far from stretched and new short positions face no friction. Options positioning has turned more bullish than usual. The put/call ratio is 0.56, about one standard deviation below its 20-day average of 0.65, reflecting heavier call activity than put buying. The picture that emerges is one where shorts are accumulating but the broader market is not positioned defensively around them.

The Street remains constructive despite a series of target reductions. Morgan Stanley's Matthew Harrison, writing this morning, kept his Overweight rating while trimming his price target to $213 from $218. That follows Barclays cutting to $207 from $237 at the end of September and JP Morgan lowering to $175 in August. Most of those reductions came after the August earnings beat, when the stock surged 32% in a single session, and reflect recalibration of commercial assumptions rather than a change in direction. The analyst consensus is still heavily skewed toward Buy-equivalent ratings, with a mean target of $196 against a current price of $95.67. Wolfe Research's downgrade to Peer Perform on October 12 remains the clearest bearish flag from the Street, and no price target accompanied it. The bull case rests on Brinsupri sustaining momentum, a peak revenue model now above $7 billion, and upside from TPIP in pulmonary arterial hypertension. Bears point to undisclosed one-year persistence data, gross-to-net pressure widening past the mid-to-high 20s into 2027, and execution risk on frontline Arikayce approvals in the US and Japan.

Medicaid reimbursement data from the Centers for Medicare and Medicaid Services adds one concrete data point to the commercial picture. CMS records show Medicaid units reimbursed for the relevant drug rose more than 12,000% in Q1 2026 against Q1 last year, and Medicaid dollars reimbursed rose 184% over the same period. The absolute dollar figure is modest at roughly $11.6 million, but the rate of change reflects a product moving from near-zero utilisation into a measurable patient population. None of the three alternative datasets tracked for Insmed carry a measured lead status against the company's reported figures, so this Medicaid data is context, not a predictor of the upcoming print.

One wrinkle in the index picture is worth noting. ORTEX puts a 52% chance on Insmed leaving both the CRSP US Large and CRSP US Mid indices at the December 2026 Quarterly Review, with a combined potential selling flow of roughly $263 million from index trackers. The price that decides it is $96.76, and Insmed closed Tuesday at $95.67, putting it 1.1% below that exit line. A simultaneous 52% probability exists for a share-count increase in the CRSP US Small index, which would bring $332 million in buying from that direction. These are ORTEX forecasts, not index provider announcements, and the rank date is December 4. The proximity of the current price to the $96.76 threshold means the December outcome depends partly on what the October 29 print does to the share price.

The August earnings reaction, a 32% single-day move followed by a 28% gain over five days, sets a high-water mark for how much the stock can move on a result. Short interest has nearly doubled since those figures were published. The gap between the current price and the mean analyst target is wider than it has been for most of the year. Whether that gap closes or widens is the question that positions on both sides of the order book are now priced around, with eight days left before the answer arrives.